Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder

Abbey Berenson, Humera Asem, Alai Tan, Gregg S. Wilkinson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To estimate continuation rates, complications, and psychiatric hospitalizations among women with bipolar disorder using levonorgestrel- releasing or copper-containing intrauterine devices (IUDs) as compared with those using depot medroxyprogesterone acetate or sterilization for birth control. Methods: Data for this cohort study were obtained from a nationwide health insurance claims database on an employed, commercially insured population. Women aged 18-44 years with a prior diagnosis of bipolar disorder (n=849) who were using the levonorgestrel intrauterine system, a copper-containing IUD, depot medroxyprogesterone acetate, or sterilization were evaluated. Outcomes included continuation rates over a 12-month interval, infectious and noninfectious complications, and hospitalizations for bipolar disorder or depression. Results: Women using an IUD were more likely than those using depot medroxyprogesterone acetate to continue the method for at least 12 months (copper-containing IUD, 86%; levonorgestrel intrauterine system, 87%). In comparison, only 31% of those who initiated depot medroxyprogesterone acetate received three more injections during the next year (P<.001). No significant differences were noted in infectious or noninfectious complications by contraceptive type. Finally, no differences were observed in the number of hospitalizations for bipolar disorder or depression among the four contraceptive groups. Conclusion: More women with bipolar disorder continued using IUDs at one year than women using depot medroxyprogesterone acetate. The rates of complications and psychiatric hospitalizations were not different among women using an IUD, depot medroxyprogesterone acetate, or sterilization.

Original languageEnglish (US)
Pages (from-to)1331-1336
Number of pages6
JournalObstetrics and Gynecology
Volume118
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Medroxyprogesterone Acetate
Contraception
Bipolar Disorder
Copper Intrauterine Devices
Levonorgestrel
Intrauterine Devices
Hospitalization
Contraceptive Agents
Psychiatry
Health Insurance
Cohort Studies
Databases
Injections
Population

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. / Berenson, Abbey; Asem, Humera; Tan, Alai; Wilkinson, Gregg S.

In: Obstetrics and Gynecology, Vol. 118, No. 6, 12.2011, p. 1331-1336.

Research output: Contribution to journalArticle

Berenson, Abbey ; Asem, Humera ; Tan, Alai ; Wilkinson, Gregg S. / Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder. In: Obstetrics and Gynecology. 2011 ; Vol. 118, No. 6. pp. 1331-1336.
@article{fd1fd520bed047dda9bf30b3d0f5ee56,
title = "Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder",
abstract = "Objective: To estimate continuation rates, complications, and psychiatric hospitalizations among women with bipolar disorder using levonorgestrel- releasing or copper-containing intrauterine devices (IUDs) as compared with those using depot medroxyprogesterone acetate or sterilization for birth control. Methods: Data for this cohort study were obtained from a nationwide health insurance claims database on an employed, commercially insured population. Women aged 18-44 years with a prior diagnosis of bipolar disorder (n=849) who were using the levonorgestrel intrauterine system, a copper-containing IUD, depot medroxyprogesterone acetate, or sterilization were evaluated. Outcomes included continuation rates over a 12-month interval, infectious and noninfectious complications, and hospitalizations for bipolar disorder or depression. Results: Women using an IUD were more likely than those using depot medroxyprogesterone acetate to continue the method for at least 12 months (copper-containing IUD, 86{\%}; levonorgestrel intrauterine system, 87{\%}). In comparison, only 31{\%} of those who initiated depot medroxyprogesterone acetate received three more injections during the next year (P<.001). No significant differences were noted in infectious or noninfectious complications by contraceptive type. Finally, no differences were observed in the number of hospitalizations for bipolar disorder or depression among the four contraceptive groups. Conclusion: More women with bipolar disorder continued using IUDs at one year than women using depot medroxyprogesterone acetate. The rates of complications and psychiatric hospitalizations were not different among women using an IUD, depot medroxyprogesterone acetate, or sterilization.",
author = "Abbey Berenson and Humera Asem and Alai Tan and Wilkinson, {Gregg S.}",
year = "2011",
month = "12",
doi = "10.1097/AOG.0b013e318233beae",
language = "English (US)",
volume = "118",
pages = "1331--1336",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Continuation rates and complications of intrauterine contraception in women diagnosed with bipolar disorder

AU - Berenson, Abbey

AU - Asem, Humera

AU - Tan, Alai

AU - Wilkinson, Gregg S.

PY - 2011/12

Y1 - 2011/12

N2 - Objective: To estimate continuation rates, complications, and psychiatric hospitalizations among women with bipolar disorder using levonorgestrel- releasing or copper-containing intrauterine devices (IUDs) as compared with those using depot medroxyprogesterone acetate or sterilization for birth control. Methods: Data for this cohort study were obtained from a nationwide health insurance claims database on an employed, commercially insured population. Women aged 18-44 years with a prior diagnosis of bipolar disorder (n=849) who were using the levonorgestrel intrauterine system, a copper-containing IUD, depot medroxyprogesterone acetate, or sterilization were evaluated. Outcomes included continuation rates over a 12-month interval, infectious and noninfectious complications, and hospitalizations for bipolar disorder or depression. Results: Women using an IUD were more likely than those using depot medroxyprogesterone acetate to continue the method for at least 12 months (copper-containing IUD, 86%; levonorgestrel intrauterine system, 87%). In comparison, only 31% of those who initiated depot medroxyprogesterone acetate received three more injections during the next year (P<.001). No significant differences were noted in infectious or noninfectious complications by contraceptive type. Finally, no differences were observed in the number of hospitalizations for bipolar disorder or depression among the four contraceptive groups. Conclusion: More women with bipolar disorder continued using IUDs at one year than women using depot medroxyprogesterone acetate. The rates of complications and psychiatric hospitalizations were not different among women using an IUD, depot medroxyprogesterone acetate, or sterilization.

AB - Objective: To estimate continuation rates, complications, and psychiatric hospitalizations among women with bipolar disorder using levonorgestrel- releasing or copper-containing intrauterine devices (IUDs) as compared with those using depot medroxyprogesterone acetate or sterilization for birth control. Methods: Data for this cohort study were obtained from a nationwide health insurance claims database on an employed, commercially insured population. Women aged 18-44 years with a prior diagnosis of bipolar disorder (n=849) who were using the levonorgestrel intrauterine system, a copper-containing IUD, depot medroxyprogesterone acetate, or sterilization were evaluated. Outcomes included continuation rates over a 12-month interval, infectious and noninfectious complications, and hospitalizations for bipolar disorder or depression. Results: Women using an IUD were more likely than those using depot medroxyprogesterone acetate to continue the method for at least 12 months (copper-containing IUD, 86%; levonorgestrel intrauterine system, 87%). In comparison, only 31% of those who initiated depot medroxyprogesterone acetate received three more injections during the next year (P<.001). No significant differences were noted in infectious or noninfectious complications by contraceptive type. Finally, no differences were observed in the number of hospitalizations for bipolar disorder or depression among the four contraceptive groups. Conclusion: More women with bipolar disorder continued using IUDs at one year than women using depot medroxyprogesterone acetate. The rates of complications and psychiatric hospitalizations were not different among women using an IUD, depot medroxyprogesterone acetate, or sterilization.

UR - http://www.scopus.com/inward/record.url?scp=81855161526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855161526&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e318233beae

DO - 10.1097/AOG.0b013e318233beae

M3 - Article

C2 - 22105263

AN - SCOPUS:81855161526

VL - 118

SP - 1331

EP - 1336

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -